Stimulation of endogenous insulin secretion by subcutaneous AC2993 (synthetic exendin-4) in healthy overnight fasted volunteers

被引：0

|

作者：

Kolterman, O

Young, G

Parker, J

Amin, D

Prickett, K

机构：

来源：

DIABETES | 1999年 / 48卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0861

引用

收藏

页码：A199 / A199

页数：1

相关论文

共 21 条

[1] AC2993 (synthetic exendin-4) modulates β-cell mass in insulin resistant fa/fa rats
不详
CELL BIOCHEMISTRY AND BIOPHYSICS, 2004, : 250 - 250
[2] Population modeling to guide Phase 3 dose selection for AC2993 (synthetic exendin-4).
Phillips, L
Fineman, M
Taylor, K
Baron, A
Ludwig, E
Grasela, T
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P29 - P29
[3] Exendin-4 (AC2993) decreases glucagon secretion during hyperglycemic clamps in Diabetic Fatty Zucker rats
Gedulin, B
Jodka, L
Hoyt, J
DIABETES, 1999, 48 : A199 - A199
[4] Dose-response for inhibition of glucagon secretion and gastric emptying by synthetic exendin-4 (AC2993) in subjects with type 2 diabetes
Kolterman, O
Gottlieb, A
Prickett, K
Gaines, E
Young, A
DIABETES, 2000, 49 : A114 - A114
[5] Effects of five-day dosing of synthetic exendin-4 (AC2993) in people with type 2 diabetes
Buse, J
Fineman, M
Gottlieb, A
Gaines, E
Kolterman, O
DIABETES, 2000, 49 : A100 - +
[6] Degradation of AC2993 (synthetic exendin-4) in mice, rat, rabbit and monkey kidney membrane preparations.
McCowen, K
Copley, K
Hiles, R
TOXICOLOGICAL SCIENCES, 2003, 72 : 349 - 349
[7] Exendin-4 (AC2993) improves insulin sensitivity in insulin resistant fatty zucker (falfa) rats independently of glycemic improvement
Gedulin, B
Smith, P
Hoyt, J
Nikoulina, S
Gedulin, G
Young, A
Parkes, D
DIABETOLOGIA, 2002, 45 : A217 - A217
[8] Continuous subcutaneous infusion of AC2993 (Synthetic exendin-4) provides sustained, day-long glycemic control to patients with type 2 diabetes
Taylor, K
Kim, D
Bicsak, T
Heintz, S
Varns, A
Aisporna, M
Fineman, MS
Baron, A
DIABETES, 2002, 51 : A85 - A85
[9] Parotid gland basophilic foci in mice administered the peptide AC2993 (synthetic exendin-4) by subcutaneous injection for periods of 13 to 26 weeks.
Hiles, R
Slone, T
Serota, D
TOXICOLOGICAL SCIENCES, 2003, 72 : 384 - 384
[10] AC2993 (synthetic exendin-4) lowered postprandial plasma glucose concentrations in people with type 2 diabetes.
Kolterman, O
Fineman, M
Gottlieb, A
Petrella, E
Pricket, K
Young, A
DIABETOLOGIA, 1999, 42 : A41 - A41